vs
Side-by-side financial comparison of Cardinal Health (CAH) and Elevance Health (ELV). Click either name above to swap in a different company.
Cardinal Health is the larger business by last-quarter revenue ($65.6B vs $49.7B, roughly 1.3× Elevance Health). Elevance Health runs the higher net margin — 1.1% vs 0.7%, a 0.4% gap on every dollar of revenue. On growth, Cardinal Health posted the faster year-over-year revenue change (19.6% vs 1.8%). Over the past eight quarters, Cardinal Health's revenue compounded faster (6.9% CAGR vs 6.5%).
Cardinal Health, Inc. is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products.
Elevance Health, Inc. is an American health insurance company. Prior to June 2022, Elevance Health was named Anthem, Inc. The company is the world's seventh largest healthcare company based on revenue. Its services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans through affiliated companies such as Anthem Blue Cross and Blue Shield, Anthem Blue Cross in California, Wellpoint, and Carelon.
CAH vs ELV — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $65.6B | $49.7B |
| Net Profit | $467.0M | $547.0M |
| Gross Margin | 3.7% | 88.9% |
| Operating Margin | 1.1% | 0.6% |
| Net Margin | 0.7% | 1.1% |
| Revenue YoY | 19.6% | 1.8% |
| Net Profit YoY | -7.7% | -74.9% |
| EPS (diluted) | — | $2.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $49.7B | ||
| Q4 25 | $65.6B | $49.7B | ||
| Q3 25 | — | $50.7B | ||
| Q2 25 | $60.2B | $49.8B | ||
| Q1 25 | $54.9B | $48.9B | ||
| Q4 24 | $55.3B | $45.4B | ||
| Q3 24 | $52.3B | $45.1B | ||
| Q2 24 | $59.7B | $43.9B |
| Q1 26 | — | $547.0M | ||
| Q4 25 | $467.0M | $547.0M | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $239.0M | $1.7B | ||
| Q1 25 | $506.0M | $2.2B | ||
| Q4 24 | $400.0M | $418.0M | ||
| Q3 24 | $416.0M | $1.0B | ||
| Q2 24 | $236.0M | $2.3B |
| Q1 26 | — | 88.9% | ||
| Q4 25 | 3.7% | 88.9% | ||
| Q3 25 | — | 89.4% | ||
| Q2 25 | 3.7% | 89.4% | ||
| Q1 25 | 3.9% | 89.8% | ||
| Q4 24 | 3.5% | 86.8% | ||
| Q3 24 | 3.6% | 88.7% | ||
| Q2 24 | 3.1% | 89.0% |
| Q1 26 | — | 0.6% | ||
| Q4 25 | 1.1% | 0.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 0.7% | 4.9% | ||
| Q1 25 | 1.3% | 6.5% | ||
| Q4 24 | 1.0% | 1.5% | ||
| Q3 24 | 1.1% | 3.1% | ||
| Q2 24 | 0.7% | 6.3% |
| Q1 26 | — | 1.1% | ||
| Q4 25 | 0.7% | 1.1% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | 0.4% | 3.5% | ||
| Q1 25 | 0.9% | 4.5% | ||
| Q4 24 | 0.7% | 0.9% | ||
| Q3 24 | 0.8% | 2.3% | ||
| Q2 24 | 0.4% | 5.2% |
| Q1 26 | — | $2.56 | ||
| Q4 25 | — | $2.56 | ||
| Q3 25 | — | $5.32 | ||
| Q2 25 | — | $7.72 | ||
| Q1 25 | — | $9.61 | ||
| Q4 24 | — | $1.88 | ||
| Q3 24 | $1.70 | $4.36 | ||
| Q2 24 | $0.86 | $9.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.8B | $9.5B |
| Total DebtLower is stronger | $8.3B | $31.9B |
| Stockholders' EquityBook value | $-2.9B | $43.9B |
| Total Assets | $58.1B | $121.5B |
| Debt / EquityLower = less leverage | — | 0.73× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $9.5B | ||
| Q4 25 | $2.8B | $9.5B | ||
| Q3 25 | — | $8.7B | ||
| Q2 25 | $3.9B | $8.6B | ||
| Q1 25 | $3.3B | $7.5B | ||
| Q4 24 | $3.8B | $8.3B | ||
| Q3 24 | $2.9B | $7.9B | ||
| Q2 24 | $5.3B | $6.5B |
| Q1 26 | — | $31.9B | ||
| Q4 25 | $8.3B | $31.9B | ||
| Q3 25 | — | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.1B | — | ||
| Q4 24 | $7.1B | $30.9B | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $4.7B | — |
| Q1 26 | — | $43.9B | ||
| Q4 25 | $-2.9B | $43.9B | ||
| Q3 25 | — | $44.0B | ||
| Q2 25 | $-2.8B | $43.7B | ||
| Q1 25 | $-2.9B | $42.5B | ||
| Q4 24 | $-3.0B | $41.3B | ||
| Q3 24 | $-3.3B | $43.8B | ||
| Q2 24 | $-3.2B | $42.2B |
| Q1 26 | — | $121.5B | ||
| Q4 25 | $58.1B | $121.5B | ||
| Q3 25 | — | $122.7B | ||
| Q2 25 | $53.1B | $121.9B | ||
| Q1 25 | $49.9B | $119.7B | ||
| Q4 24 | $47.0B | $116.9B | ||
| Q3 24 | $43.1B | $116.5B | ||
| Q2 24 | $45.1B | $113.0B |
| Q1 26 | — | 0.73× | ||
| Q4 25 | — | 0.73× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CAH
| Pharmaceutical And Specialty Solutions | $60.7B | 92% |
| GMPD | $3.3B | 5% |
| At Home Solutions | $1.2B | 2% |
| Nuclear Precision Health Solutions | $440.0M | 1% |
| Opti Freight Logistics | $99.0M | 0% |
ELV
Segment breakdown not available.
